Japan's health ministry has fixed a price for Oncolys BioPharma's esophageal cancer cell therapy, development code OBP-301, clearing the last hurdle before the company can start booking sales.
The regenerative-medicine product was added to the National Health Insurance drug price list through an Official Gazette notice on August 12, 2026, following the Central Social Insurance Medical Council's approval of the price proposal on August 5. Insurance coverage takes effect August 13, at a unit price of ¥3.1mn, or ¥9.3mn per patient.
| Item | Detail |
|---|---|
| NHI unit price | ¥3.1mn (¥3,102,489) |
| Price per patient | ¥9.3mn (¥9,307,467) |
| Insurance coverage start | August 13, 2026 |
| Sales launch | August 21, 2026, via Fujifilm Toyama Chemical |
| Revenue booking | Fiscal year ending December 2026 |
Oncolys plans to launch sales on August 21 through marketing partner Fujifilm Toyama Chemical. The company expects to start recording product sales revenue in the fiscal year ending December 2026, though it says the precise effect on its financial forecasts is still being worked out.
For a company that has spent years developing an oncolytic virus therapy, the price list entry is the point where biotech research becomes an invoice. At ¥9.3mn a patient, how many hospitals prescribe it, and how insurers handle the reimbursement load, will decide whether the launch date on the calendar turns into meaningful revenue.